Simone Filosto
Overview
Explore the profile of Simone Filosto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian Y, Budka J, Locke F, Westin J, To C, Tiwari G, et al.
Front Oncol
. 2025 Mar;
15:1519473.
PMID: 40083872
Introduction: CAR T cell therapy provided transformative outcomes for patients with B-cell lymphoma; however, a large fraction of patients remains at risk for relapse, underlying the need to uncover mechanisms...
2.
Frigault M, Yao E, Berger T, Wehrli M, Gallagher K, Horick N, et al.
Blood Adv
. 2025 Feb;
PMID: 39928957
Chimeric antigen receptor T (CAR-T) cell therapy is limited by cytokine release syndrome (CRS) and neurotoxicity (NT). We sought to use once-daily prophylactic anakinra, an IL-1R antagonist, to prevent CRS/NT...
3.
Stewart C, Siegler E, Sakemura R, Cox M, Huynh T, Kimball B, et al.
Nat Commun
. 2024 Sep;
15(1):7921.
PMID: 39266501
Durable response to chimeric antigen receptor T (CART) cell therapy remains limited in part due to CART cell exhaustion. Here, we investigate the regulation of CART cell exhaustion with three...
4.
Chartier M, Filosto S, Peyret T, Chiney M, Milletti F, Budka J, et al.
Clin Pharmacokinet
. 2024 Sep;
63(9):1283-1299.
PMID: 39240498
Background And Objective: Axicabtagene ciloleucel (axi-cel, Yescarta) is an autologous, anti-CD19, chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed and refractory non-Hodgkin's lymphoma. Substantial inter-individual variability in...
5.
Locke F, Oluwole O, Kuruvilla J, Thieblemont C, Morschhauser F, Salles G, et al.
Blood
. 2024 Apr;
143(24):2464-2473.
PMID: 38557775
Metabolic tumor volume (MTV) assessed using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography, a measure of tumor burden, is a promising prognostic indicator in large B-cell lymphoma (LBCL). This exploratory analysis evaluated relationships...
6.
Locke F, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, et al.
Nat Med
. 2024 Jan;
30(2):507-518.
PMID: 38233586
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed...
7.
Filosto S, Vardhanabhuti S, Canales M, Poire X, Lekakis L, de Vos S, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):21-33.
PMID: 37983485
Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower...
8.
Jain M, Miklos D, Jacobson C, Timmerman J, Sun J, Nater J, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4118-4127.
PMID: 37527011
Purpose: Chimeric antigen receptor (CAR) T-cell therapies have shown clinical benefit for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), yet approximately 60% of patients do not respond or eventually...
9.
Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A, et al.
N Engl J Med
. 2023 Jun;
389(2):148-157.
PMID: 37272527
Background: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19...
10.
Westin J, Locke F, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, et al.
Clin Cancer Res
. 2023 Mar;
29(10):1894-1905.
PMID: 36999993
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of...